Effects of malignancies on fertility preservation outcomes and relevant cryobiological advances  

作　　者：Dongming Liu Jie Yan Jie Qiao 

机构地区：[1]Reproductive Medical Center,Department of Obstetrics and Gynecology,Peking University Third Hospital,Beijing 100191,China [2]National Clinical Center for Obstetrics and Gynecology,Beijing 100191,China [3]Key Laboratory of Assisted Reproduction,Ministry of Education,Beijing 100191,China [4]Beijing Key Laboratory of Reproductive Endocrinology and Assisted Reproduction,Beijing 100191,China

出　　处：《Science China(Life Sciences)》2020年第2期217-227,共11页中国科学（生命科学英文版）

基　　金：supported by the National Key Technology R&D Program of China(2017YFC1002004,2018YFC1004001);National Natural Science Foundation of China(81571386,81730038,31429004)。

摘　　要：A decrease in cancer deaths has resulted in the possibility of child bearing for many young adult cancer survivors. Most antitumor treatment modalities are detrimental to female fertility, and methods for fertility preservation before gonadotoxic treatment, including cryopreservation of oocytes, embryos and ovarian tissue, have therefore been developed. This review focuses on the ovarian function of cancer patients, the safety and efficacy of fertility preservation methods, and the pregnancy outcomes of these patients. Breast cancer and hematological tumors constitute the majority of cancers in reproductive-aged female oncology patients. Ovarian function may not be impacted by breast cancer cells, while in patients with hematological malignancies, decreases in anti-Müllerian hormone and antral follicle counts have been demonstrated. In most cases, patients can undergo ovarian stimulation without delaying treatment, and a new stimulation protocol known as dual stimulation, which may be more efficient, has now been developed. Birth outcomes are also acceptable in cancer patients.A decrease in cancer deaths has resulted in the possibility of child bearing for many young adult cancer survivors. Most antitumor treatment modalities are detrimental to female fertility, and methods for fertility preservation before gonadotoxic treatment, including cryopreservation of oocytes, embryos and ovarian tissue, have therefore been developed. This review focuses on the ovarian function of cancer patients, the safety and efficacy of fertility preservation methods, and the pregnancy outcomes of these patients. Breast cancer and hematological tumors constitute the majority of cancers in reproductive-aged female oncology patients. Ovarian function may not be impacted by breast cancer cells, while in patients with hematological malignancies, decreases in anti-Müllerian hormone and antral follicle counts have been demonstrated. In most cases, patients can undergo ovarian stimulation without delaying treatment, and a new stimulation protocol known as dual stimulation, which may be more efficient, has now been developed. Birth outcomes are also acceptable in cancer patients.

关 键 词：cancer patients FERTILITY PRESERVATION controlled OVARIAN stimulation safety 

分 类 号：R730.5[医药卫生—肿瘤]